Research output per year
Research output per year
Personal profile
Education/Academic qualification
Integrated Health Resources Management Diploma, ESADE Business
Award Date: 15 Jan 2007
Ph. D., Doctorat, Universitat Autònoma de Barcelona (UAB)
Award Date: 1 Jan 1993
Neurology Resident, MIR Program, Vall d’Hebron University Hospital, Barcelona, Spain, Vall d'Hebron University Hospital (HUVH)
Award Date: 30 Jun 1988
Degree, Llicenciat, Universitat Autònoma de Barcelona (UAB)
Award Date: 1 Jan 1983
Fingerprint
Dive into the research topics where Xavier Montalban Gairin is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis
Magnetic Resonance Imaging Network in Multiple Sclerosis, Consortium of Multiple Sclerosis Centres & North American Imaging in Multiple Sclerosis Cooperative MRI guidelines working group, 1 Oct 2025, In: The Lancet Neurology. 24, 10, p. 866-879 14 p.Research output: Contribution to journal › Article › Research
6 Citations (Scopus) -
Advancing multiple sclerosis management in older adults
International Advisory Committee Clinical Trials in MS Workshop on Ageing and MS members, 23 Jul 2025, In: Nature Reviews Neurology. 21, 8, p. 432-448 17 p.Research output: Contribution to journal › Review article › Research › peer-review
Open Access3 Citations (Scopus) -
Age-Related Disability Outcomes After a First Demyelinating Event
Cobo-Calvo, A., Carbonell-Mirabent, P., Tur, C., Otero-Romero, S., Carvajal, R., Arrambide, G., Ariño, H., Auger, C., Villacieros-Álvarez, J., Bollo, L., Castilló, J., Comabella, M., Espejo, C., Fernández, V., Guio-Sánchez, C., Galan, I., La Puma, D., Midaglia, L. S., Mongay-Ochoa, N. & Vilaseca, A. & 12 others, , 25 Feb 2025, In: Neurology. 104, 4, 13 p., e210305.Research output: Contribution to journal › Article › Research › peer-review
1 Citation (Scopus) -
AI-driven reclassification of multiple sclerosis progression
Ganjgahi, H., Häring, D. A., Aarden, P., Graham, G., Sun, Y., Gardiner, S., Su, W., Berge, C., Bischof, A., Fisher, E., Gaetano, L., Thoma, S. P., Kieseier, B. C., Nichols, T. E., Thompson, A. J., Montalban, X., Lublin, F. D., Kappos, L., Arnold, D. L. & Bermel, R. A. & 2 others, , 20 Aug 2025, In: Nature Medicine. 31, p. 3414-3424 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access1 Citation (Scopus) -
An expert patient program for people living with multiple sclerosis improves knowledge and empowerment: a pre-test, post-test multicenter implementation study
Robles-Sánchez, M. Á., Amil-Bujan, P., Bosch-Farré, C., Coll-Martínez, C., Arévalo, M. J., Anglada-Clofent, E., Menéndez-Díaz, R., Aroca-Alsina, M., Merchan-Ruiz, M., Pérez-Hoyos, S., Arévalo-Bernabé, Á. G., Montalban, X., Hernando, A., LLufriú, S., Peralta-Moncusí, S., Brieva, L., Ramo-Tello, C., Carabí, M., Solà-Valls, N. & Zabay, M. C. & 4 others, , 29 Apr 2025, In: Frontiers in Neurology. 16, 16 p., 1581038.Research output: Contribution to journal › Article › Research › peer-review
Open Access
Datasets
-
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
Gold, R. (Creator), Radue, E.-W. (Contributor), Giovannoni, G. (Creator), Selmaj, K. (Creator), Havrdova, E. (Creator), Stefoski, D. (Contributor), Sprenger, T. (Creator), Montalban, X. (Creator), Cohan, S. (Creator), Umans, K. (Creator), Greenberg, S. J. (Creator), Ozen, G. (Contributor) & Elkins, J. (Creator), figshare, 26 Jul 2016
DOI: 10.6084/m9.figshare.c.3618185.v1, https://figshare.com/collections/Safety_and_efficacy_of_daclizumab_in_relapsing-remitting_multiple_sclerosis_3-year_results_from_the_SELECTED_open-label_extension_study/3618185/1
Dataset
-
Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis
Meaton, I. (Creator), Altokhis, A. (Creator), Allen, C. M. (Creator), Clarke, M. A. (Creator), Sinnecker, T. (Creator), Meier, D. (Creator), Enzinger, C. (Creator), Calabrese, M. (Creator), De Stefano, N. (Creator), Pitiot, A. (Creator), Giorgio, A. (Creator), Schoonheim, M. M. (Creator), Paul, F. (Creator), Pawlak, M. A. (Creator), Schmidt, R. (Creator), Granziera, C. (Creator), Kappos, L. (Creator), Montalban, X. (Creator), Rovira, À. (Creator), Wuerfel, J. (Creator) & Evangelou, N. (Creator), SAGE Journals, 27 Aug 2022
DOI: 10.25384/sage.c.6169222.v1, https://sage.figshare.com/collections/Paramagnetic_rims_are_a_promising_diagnostic_imaging_biomarker_in_multiple_sclerosis/6169222/1
Dataset
-
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Cree, B. A. (Creator), Selmaj, K. W. (Creator), Steinman, L. (Creator), Comi, G. (Creator), Bar-Or, A. (Creator), Arnold, D. L. (Creator), Hartung, H.-P. (Creator), Montalbán, X. (Creator), Havrdová, E. K. (Creator), Sheffield, J. K. (Creator), Minton, N. (Creator), Cheng, C.-Y. (Creator), Silva, D. (Creator), Kappos, L. (Creator) & Cohen, J. A. (Creator), SAGE Journals, 1 Jul 2022
DOI: 10.25384/sage.c.6074109.v1, https://sage.figshare.com/collections/Long-term_safety_and_efficacy_of_ozanimod_in_relapsing_multiple_sclerosis_Up_to_5_years_of_follow-up_in_the_DAYBREAK_open-label_extension_trial/6074109/1
Dataset
-
Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II
Gärtner, J. (Creator), Hauser, S. L. (Creator), Bar-Or, A. (Creator), Montalban, X. (Creator), Cohen, J. A. (Creator), Cross, A. H. (Creator), Deiva, K. (Creator), Ganjgahi, H. (Creator), Häring, D. A. (Creator), Li, B. (Creator), Pingili, R. (Creator), Ramanathan, K. (Creator), Su, W. (Creator), Willi, R. (Creator), Kieseier, B. (Creator) & Kappos, L. (Creator), SAGE Journals, 11 Mar 2022
DOI: 10.25384/sage.c.5889512.v1, https://sage.figshare.com/collections/Efficacy_and_safety_of_ofatumumab_in_recently_diagnosed_treatment-naive_patients_with_multiple_sclerosis_Results_from_ASCLEPIOS_I_and_II/5889512/1
Dataset
-
Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study
Gold, R. (Creator), Radue, E.-W. (Contributor), Giovannoni, G. (Creator), Selmaj, K. (Creator), Havrdova, E. (Creator), Stefoski, D. (Contributor), Sprenger, T. (Creator), Montalban, X. (Creator), Cohan, S. (Creator), Umans, K. (Creator), Greenberg, S. J. (Creator), Ozen, G. (Contributor) & Elkins, J. (Creator), figshare, 26 Jul 2016
DOI: 10.6084/m9.figshare.c.3618185, https://figshare.com/collections/Safety_and_efficacy_of_daclizumab_in_relapsing-remitting_multiple_sclerosis_3-year_results_from_the_SELECTED_open-label_extension_study/3618185
Dataset